Cedazuridine manufacturers
- Cedazuridine
-
- $50.00
-
2026-07-15
- CAS:1141397-80-9
- Purity: 99.66%
- Supply Ability: 10g
|
| | Cedazuridine Basic information |
| Product Name: | Cedazuridine | | Synonyms: | (R)-1-((2R, 4R, SR)-3,3-difluoro-4-hydroxy (hydroxymethyl) tetrahydrofuran-2-yl)-4-hydroxytetrahydropyrimidin-2(1H)-one;Cedazuridine
(E7727;E 7727);Uridine, 2'-deoxy-2',2'-difluoro-3,4,5,6-tetrahydro-, (4R)-;2’-deoxy-2’,2’-difluorotetrahydrouridine;Clascoterone Impurity 38;(4R)-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one;Cedazuridine, 10 mM in DMSO | | CAS: | 1141397-80-9 | | MF: | C9H14F2N2O5 | | MW: | 268.21 | | EINECS: | 822-329-6 | | Product Categories: | | | Mol File: | 1141397-80-9.mol |  |
| | Cedazuridine Chemical Properties |
| Boiling point | 597.7±50.0 °C(Predicted) | | density | 1+-.0.1 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO : 50 mg/mL (186.42 mM; ultrasonic and warming and heat to 60°C) | | pka | 11.72±0.70(Predicted) | | form | Solid | | color | White to off-white | | InChI | InChI=1S/C9H12F2N2O5/c10-9(11)6(16)4(3-14)18-7(9)13-2-1-5(15)12-8(13)17/h4,6-7,14,16H,1-3H2,(H,12,15,17)/t4-,6-,7-/m1/s1 | | InChIKey | VQSLORATCUBFCL-QPPQHZFASA-N | | SMILES | OC[C@H]1O[C@@H](N2CCC(=O)NC2=O)[C@](F)(F)[C@@H]1O |
| | Cedazuridine Usage And Synthesis |
| Uses | Cedazuridine (E7727) (Compound 7a) is an orally active cytidine deaminase (CDA) inhibitor with an IC50 value of 0.4 μM. Cedazuridine can be used for cancer research[1]. | | Mechanism of action |
Cedazuridine increases the half-life of decitabine by inhibiting cytosine deaminase, thereby improving the efficacy of combination therapy and having a better therapeutic effect than decitabine alone.
| | Synthesis |
The synthesis began with the readily available protected gemcitabine precursor 244. The 6-aminopyridine was converted to the corresponding dihydrouracil 245 in 97% yield via acid-mediated transfer hydrogenation. Reduction under Luche conditions followed by treatment with methanolic ammonia reduced the amide carbonyl group and removed the two phenoxyester protecting groups to afford dihydrouracil 246 as a mixture of two diastereoisomers. Treatment of 246 with a catalytic amount of DBU in aqueous acetonitrile afforded a diastereomeric mixture in which cedaruridine and its cyclic amino alcohol 247 were present in a 9:1 ratio. Reconstitution of the undesired diastereomer 247 in a cold acetonitrile/water mixture (5:1) afforded cedaruridine in 86% yield.
| | in vivo | Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models[2]. | Animal Model: | Female NSGS mice, 6–8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models[2] | | Dosage: | 3 mg/kg | | Administration: | Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days | | Result: | Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model. |
| Animal Model: | NSGS male mice[2] | | Dosage: | 1, 3, 10 and 30 mg/kg | | Administration: | Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies) | | Result: | Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA. |
| | References | [1] Ferraris D, et al. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J Med Chem. 2014 Mar 27; 57(6):2582-8. DOI:10.1021/jm401856k
[2] Ramsey H E, et al. Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model. Targeted Oncology, 2020, 15(2): 231-240. |
| | Cedazuridine Preparation Products And Raw materials |
|